Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Illumina, Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.2× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and Illumina, Inc. for 83 Days on average.
| HYG | ILMN | |
|---|---|---|
Market Cap | $17.89B | $39.95B |
Volume | 44,866,592 | 3,169,503 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $293.69 |
52-Week Low | $76.90 | $91.00 |
Typical Hold Time | 60 Days | 83 Days |
Enterprise Value | — | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.14, down 0.05% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains consistent dividend distributions with recent payouts ranging from $0.38 to $0.44. Market sentiment is heavily influenced by the broader bond selloff as Treasury yields reach multi-decade highs, creating headwinds for high-yield corporate bonds.
Current market conditions present challenges for HYG as rising interest rates pressure high-yield bond valuations. The ETF's performance remains tied to Federal Reserve policy and corporate credit conditions, with upside potential limited until bond market volatility subsides. Key risks include further rate hikes and economic slowdown impacting junk bond issuers.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
